There are no HER3 directed therapies approved for the treatment of NSCLC or any cancer. The frequency of HER3 overexpression in EGFR-mutated NSCLC has been reported to be as high as 75 percent, and there is evidence that HER3 expression may be associated with resistance to TKIs.[1],[2]
'The majority of patients with activating mutations of EGFR, or EGFR-mutated NSCLC, overexpress the HER3 protein in the cancer cells, and there is evidence that HER3 expression is a passenger marker of resistance to TKIs. Clinical and preclinical data, as well as biomarker expression and resistance mechanism research, support the further evaluation of patritumab deruxtecan and TAGRISSO as a treatment combination for patients with EGFR-mutated NSCLC who have progressed after treatment with a TKI, typically TAGRISSO,' said
'In this trial, we will explore a new potential way to treat patients with advanced disease by combining TAGRISSO with patritumab deruxtecan, a HER3 directed ADC,' said
About the Study
Under the terms of the agreement,
The first part of the study (dose escalation) will assess the safety and tolerability of different dosing combinations of patritumab deruxtecan and TAGRISSO to determine the recommended combination dose. The second part of the study (dose expansion) will include a first-line and second-line cohort that will further evaluate the anti-tumor activity and safety of the combination. Patients enrolled in the first-line cohort will receive patritumab deruxtecan and TAGRISSO combination treatment, and patients in the second-line cohort will be randomized 1:1 to receive treatment with patritumab deruxtecan alone or in combination with TAGRISSO. Up to 258 patients will be enrolled into the study, which will be conducted in
The primary study objectives for the dose escalation part of the study include the assessment of the safety and tolerability of patritumab deruxtecan and TAGRISSO. The primary objective for the dose expansion part of the study for both cohorts is the assessment of anti-tumor activity as measured by objective response rate (ORR) and as assessed by independent central review.
Unmet Need in Non-Small Cell
Lung cancer is the most common cancer and is the leading cause of cancer mortality worldwide with an estimated 2.1 million new cases of lung cancer in 2018 and 1.8 million deaths.[3] Non-small cell lung cancer (NSCLC) accounts for 80 to 85 percent of all lung cancers.[4]
Mutations in the epidermal growth factor receptor (EGFR) gene are among the most frequently observed genomic alterations in NSCLC, affecting approximately 14 to 30 percent of patients with NSCLC.[5] For patients with EGFR-mutated NSCLC, targeted therapy with EGFR TKIs offers higher response rates, overall survival and progression-free survival compared to chemotherapy.[6] However, most patients eventually develop resistance to the TKIs, and new treatment approaches including combination strategies designed to overcome TKI resistance are needed.[7]
About HER3
HER3 is a member of the EGFR family of tyrosine kinase receptors, which are associated with normal as well as aberrant cell proliferation and survival.2 HER3 expression has been associated with an increased incidence of metastases and reduced survival in patients with NSCLC with expression frequency reported to be as high as 75 percent.1 A majority of EGFR-mutated NSCLCs show some level of HER3 expression.[8],[9] Currently, no HER3 directed therapies are approved for NSCLC or any cancer.
About Patritumab Deruxtecan (U3-1402)
Patritumab deruxtecan (U3-1402) is one of three lead DXd antibody drug conjugates (ADC) in the oncology pipeline of
ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy ('payload') to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. Designed using
Patritumab deruxtecan is currently being evaluated in a phase 1 study in previously treated patients with metastatic or unresectable NSCLC. Patritumab deruxtecan is also being evaluated in a phase 1/2 study in patients with HER3 expressing metastatic breast cancer.
Patritumab deruxtecan is an investigational agent that has not been approved for any indication in any country. Safety and efficacy have not been established.
About Daiichi Sankyo Cancer Enterprise
The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by our DXd antibody drug conjugate (ADC) technology, our powerful research engines include biologics, medicinal chemistry, modality and other research laboratories in
About
Contact:
Tel: +1 908 900 3010
Email: vamari@dsi.com
(C) 2020 Electronic News Publishing, source